Filtered By:
Management: Marketing
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 200 results found since Jan 2013.
4 Key Insights When Raising Money for Your Medtech Startup: Interview with Bruce Shook, CEO of Intact Vascular
Welcome to the Medsider interview series, a regular feature at MassDevice. All interviews are conducted by Scott Nelson, Founder of Medsider and Group Director for WCG. We hope you enjoy them!
Bruce Shook joined Intact Vascular in 2014 as President and CEO. A highly-experienced, medical device executive with more than 30 years of industry experience, Bruce was previously Co-founder, Director, President, and CEO of Neuronetics, which is a privately held medical device company that markets a non-invasive brain stimulation technology for the treatment of depression.
Previously, Shook was Co-founder, Director, President, an...
Source: Mass Device - February 27, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Blog medsider Source Type: news
7 medtech stories we missed this week: Feb. 24, 2017
[Photo from unsplash.com]Several companies made distribution deals this week, while others received approval for their products. Here are 7 medtech stories we missed this week but were still worth mentioning.
1. Israel OKs E-Qure’s BST device for chronic wounds
E-Qure Corp. announced this week that it received marketing approval for its Bio-electrical Signal Therapy Device (BST Device) from the Israeli Ministry of Health, according to a Feb. 24 news release. BST is an electrotherapeutic method for treating chronic wounds. E-Qure will begin marketing its device in Israel by activating a signed distribution agreement with...
Source: Mass Device - February 24, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Electronic Medical Records Imaging Mergers & Acquisitions mHealth (Mobile Health) Regulatory/Clearance Align Technology Clarius Mobile Health Corin Group E-Qure Henry Schein Medical Nexstim Skyline Medical Source Type: news
EMA Recommends EU Marketing of Edoxaban in Atrial Fibrillation EMA Recommends EU Marketing of Edoxaban in Atrial Fibrillation
The recommendation is for prevention of stroke and systemic embolism in atrial fibrillation and for the treatment and prevention of DVT and PE.International Approvals
Source: Medscape Medical News Headlines - February 24, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news
‘Forever Young’†—Testosterone replacement therapy: a blockbuster drug despite flabby evidence and broken promises
<span class="paragraphSection"><div class="boxTitle">Abstract</div>In the last decade, testosterone replacement therapy (TRT) has been increasingly prescribed to treat a controversial condition known as ‘late-onset hypogonadism (LOH)’. This syndrome is diagnosed in men who, for no discernible reason other than older age, obesity or ill health have serum testosterone concentrations below the normal range for healthy young men and report one or more of the following symptoms: muscle weakness or wasting, mood, behaviour and cognition-related symptoms and sexual function or libido impairment. However, rec...
Source: Human Reproduction - February 22, 2017 Category: Reproduction Medicine Source Type: research
Making Sense of Nutraceuticals in China
The Chinese nutraceutical market is considered the third largest in the world after the US and Japan, or the fourth largest if Europe is counted as a single market.Despite strong fundamentals and high rates of annual growth, though, the Chinese market remains some way from realizing its true potential. Its evolution is muddied by ambiguities around what nutraceuticals actually are and how they should be managed.The result has been polarization between over-zealous regulation of so-called health foods, and a grey market where products have skirted approval procedures through questionable positioning or by exploiting alterna...
Source: EyeForPharma - February 10, 2017 Category: Pharmaceuticals Authors: Marc Yates Source Type: news
Stop marketing our kids to death with ads for foods and drinks, Heart and Stroke urges
Canadian kids and teens are bombarded by advertising for food and beverages in movies, video games, apps and social media — and that needs to stop, according to a new report.
Source: CBC | Health - February 1, 2017 Category: Consumer Health News Tags: News/Health Source Type: news
Food and beverage industry marketing kids to deatlh
(Heart and Stroke Foundation of Canada) The Heart& Stroke 2017 Report on the Health of Canadians examines how unlimited food and beverage marketing targeted at Canadian kids is negatively affecting preferences and choices, their family relationships and their health. We commissioned one of the country's leading researchers to examine the volume of digital food and beverage advertising to Canadian children and teens, to assess the quality of the products, and to examine how well industry is regulating itself .
Source: EurekAlert! - Medicine and Health - February 1, 2017 Category: Global & Universal Source Type: news
Creative Medical Technology Holdings Files Patent on AmnioStem Stroke Therapy
PHOENIX and SAN DIEGO, Dec. 13, 2016 -- (Healthcare Sales & Marketing Network) -- Creative Medical Technology Holdings (the "Company") (CELZ) announced today filing of US patent application #62/400557 entitled "Treatment of Stroke by Amniot... Regenerative Medicine, Neurology Creative Medical Technology, AmnioStem, stem cell, exosomes, stroke
Source: HSMN NewsFeed - December 13, 2016 Category: Pharmaceuticals Source Type: news
Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies.
I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact.
Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications.
Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news
Betrixaban - the next direct factor Xa inhibitor?
Authors: Thoenes M, Minguet J, Bramlage K, Bramlage P, Ferrero C
Abstract
INTRODUCTION: Venous thromboembolism is a major global health burden. Since the 1930s, prevention of stroke and pulmonary embolism in these patients has been achieved using conventional anticoagulants, such as heparin and warfarin. However, in recent years, four direct non-vitamin K antagonist oral anticoagulants (DOACs) have entered the market as alternative treatment options. Betrixaban is a fifth DOAC looking to gain marketing approval in the near future, and may have several potentially beneficial properties. Areas covered: Here, we outli...
Source: Expert Review of Hematology - November 6, 2016 Category: Hematology Tags: Expert Rev Hematol Source Type: research
Why 5,000 People Are Suing Over Plavix
Legal action is apparently moving forward involving lawsuits filed by thousands of people who say they suffered serious injuries by taking the once-heralded blood-thinning drug Plavix.
The California Supreme Court ruled late last month that eight product liability lawsuits against Plavix manufacturer Bristol-Myers Squibb and Plavix distributor McKesson Corporation can proceed in San Francisco Superior Court.
Those eight cases involved 678 plaintiffs. They may soon be joined by a multitude of other cases, involving about 5,000 plaintiffs, that have been filed around the country.
There is no word yet on whether Bristol-My...
Source: Healthy Living - The Huffington Post - September 13, 2016 Category: Consumer Health News Source Type: news
Neuravi Announces European Launch of EmboTrap II Stent Retriever for the Treatment of Acute Stroke
GALWAY, Ireland--(Healthcare Sales & Marketing Network)--Neuravi, a company dedicated to improving clinical outcomes for stroke patients, today announced Conformité Européenne (CE) Mark approval and launch of the companys newly available enh... Devices, Neurology, Interventional, Product Launch Neuravi, EmboTrap, stroke, endovascular, stroke therapy
Source: HSMN NewsFeed - September 8, 2016 Category: Pharmaceuticals Source Type: news
FDA clears 2 clot retrieval devices for stroke
The U.S. Food and Drug Administration (FDA) said it has allowed the marketing...Read more on AuntMinnie.comRelated Reading:
Mobile stroke units, spectral CT take spots on ECRI watch list
New knowledge changes use of CT in guiding stroke treatment
Ambulance with mobile CT cuts stroke treatment times
Combination of ultrasound, tPA may boost stroke treatment
MRI software predicts stroke complications from clot busters
Source: AuntMinnie.com Headlines - September 2, 2016 Category: Radiology Source Type: news
FDA allows marketing of clot retrieval devices to reduce disability in stroke patients
The U.S. Food and Drug Administration today allowed marketing of two Trevo clot retrieval devices as an initial therapy for strokes due to blood clots (ischemic) to reduce paralysis, speech difficulties and other stroke disabilities. These devices should be used within six hours of symptom onset and only following treatment with a clot-dissolving drug (tissue plasminogen activator or t-PA), which needs to be given within three hours of symptom onset.
Source: Food and Drug Administration - September 2, 2016 Category: American Health Source Type: news
German giant Boehringer Ingelheim battles India's Gennova Biopharma over stroke treatment
Gennova recently secured marketing authorisation of tenectaplase for stroke patients in India, the first such use of the drug anywhere in the world.
Source: The Economic Times Healthcare and Biotech News - August 17, 2016 Category: Pharmaceuticals Source Type: news
